

John M Inadomi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/850259/publications.pdf>

Version: 2024-02-01

272
papers

16,222
citations

18482

62
h-index

16650

123
g-index

312
all docs

312
docs citations

312
times ranked

13153
citing authors

#	ARTICLE	IF	CITATIONS
1	An Approach to the Primary and Secondary Prevention of Gastric Cancer in the United States. Clinical Gastroenterology and Hepatology, 2022, 20, 2218-2228.e2.	4.4	19
2	Post-endoscopy Esophageal Neoplasia in Barrett's Esophagus: Consensus Statements From an International Expert Panel. Gastroenterology, 2022, 162, 366-372.	1.3	12
3	Operationalizing a Rideshare Intervention for Colonoscopy Completion: Barriers, Facilitators, and Process Recommendations. , 2022, 1, .		8
4	How to Succeed in Digestive Research. Gastroenterology, 2022, 162, 385-389.	1.3	0
5	Endoscopic Screening Program for Control of Esophageal Adenocarcinoma in Varied Populations: A Comparative Cost-Effectiveness Analysis. Gastroenterology, 2022, 163, 163-173.	1.3	7
6	Trying to Be American: A Personal Reflection of the Pervasiveness of Systemic Racism and Possible Steps to Mitigate its Impact. Gastroenterology, 2022, , .	1.3	1
7	Masculinity Barriers to Ever Completing Colorectal Cancer Screening among American Indian/Alaska Native, Black, and White Men (Ages 45-75). International Journal of Environmental Research and Public Health, 2022, 19, 3071.	2.6	6
8	Novel DNA Methylation Biomarker Panel for Detection of Esophageal Adenocarcinoma and High-Grade Dysplasia. Clinical Cancer Research, 2022, 28, 3761-3769.	7.0	2
9	The COMPASS study: A prospective, randomized, multi-center trial testing the impact of a clinic-based intervention informing patients of colorectal cancer screening options on screening completion. Contemporary Clinical Trials, 2022, 119, 106852.	1.8	0
10	Computational modelling suggests that Barrett's oesophagus may be the precursor of all oesophageal adenocarcinomas. Gut, 2021, 70, 1435-1440.	12.1	31
11	Cost-Effectiveness of Screening, Surveillance, and Endoscopic Eradication Therapies for Managing the Burden of Esophageal Adenocarcinoma. Gastrointestinal Endoscopy Clinics of North America, 2021, 31, 77-90.	1.4	5
12	What Multilevel Interventions Do We Need to Increase the Colorectal Cancer Screening Rate to 80%?. Clinical Gastroenterology and Hepatology, 2021, 19, 633-645.	4.4	22
13	Model-Based Estimation of Colorectal Cancer Screening and Outcomes During the COVID-19 Pandemic. JAMA Network Open, 2021, 4, e216454.	5.9	32
14	Surveillance Cessation for Barrett's Esophagus: A Survey of Gastroenterologists. American Journal of Gastroenterology, 2021, 116, 1730-1733.	0.4	1
15	Perceptions on Barriers and Facilitators to Colonoscopy Completion After Abnormal Fecal Immunochemical Test Results in a Safety Net System. JAMA Network Open, 2021, 4, e2120159.	5.9	14
16	The Optimal Age to Stop Endoscopic Surveillance of Patients With Barrett's Esophagus Based on Sex and Comorbidity: A Comparative Cost-Effectiveness Analysis. Gastroenterology, 2021, 161, 487-494.e4.	1.3	15
17	Screening and prevention of colorectal cancer. BMJ, The, 2021, 374, n1855.	6.0	141
18	AGA Rapid Review and Guideline for SARS-CoV2 Testing and Endoscopy Post-Vaccination: 2021 Update. Gastroenterology, 2021, 161, 1011-1029.e11.	1.3	29

#	ARTICLE	IF	CITATIONS
19	Cancer screening in the U.S. through the COVID-19 pandemic, recovery, and beyond. Preventive Medicine, 2021, 151, 106595.	3.4	23
20	The impact of cumulative colorectal cancer screening delays: A simulation study. Journal of Medical Screening, 2021, , 096914132110451.	2.3	2
21	Colorectal Cancer—Recent Advances and Future Challenges. Gastroenterology, 2020, 158, 289-290.	1.3	10
22	Optimizing Management of Patients With Barrett's Esophagus and Low-Grade or No Dysplasia Based on Comparative Modeling. Clinical Gastroenterology and Hepatology, 2020, 18, 1961-1969.	4.4	15
23	Effectiveness of a mailed fecal immunochemical test outreach: a Medicare Advantage pilot study. Therapeutic Advances in Gastroenterology, 2020, 13, 175628482094538.	3.2	12
24	AGA Institute Rapid Review and Recommendations on the Role of Pre-Procedure SARS-CoV-2 Testing and Endoscopy. Gastroenterology, 2020, 159, 1935-1948.e5.	1.3	44
25	Chemoprevention of esophageal adenocarcinoma. Gastroenterology Report, 2020, 8, 253-260.	1.3	8
26	Family History of Colorectal or Esophageal Cancer in Barrett's Esophagus and Potentially Explanatory Genetic Variants. Clinical and Translational Gastroenterology, 2020, 11, e00151.	2.5	3
27	Racial Disparities in Colorectal Cancer Mortality: the Role of Endoscopy Wait-Time and Stage at Diagnosis. Journal of Racial and Ethnic Health Disparities, 2020, 7, 967-974.	3.2	1
28	What's App with GERD?. Gastroenterology, 2020, 158, 1211-1212.	1.3	0
29	Disparities in colorectal cancer screening in New York City: An analysis of the 2014 NYC Community Health Survey. Cancer Medicine, 2019, 8, 2572-2579.	2.8	22
30	AGA Clinical Practice Guidelines on the Management of Mild-to-Moderate Ulcerative Colitis. Gastroenterology, 2019, 156, 748-764.	1.3	194
31	Implications of Epigenetic Drift in Colorectal Neoplasia. Cancer Research, 2019, 79, 495-504.	0.9	26
32	Colonoscopy Indication Algorithm Performance Across Diverse Health Care Systems in the PROSPR Consortium. EGEMS (Washington, DC), 2019, 7, 37.	2.0	5
33	American Gastroenterological Association Institute Guideline on Initial Management of Acute Pancreatitis. Gastroenterology, 2018, 154, 1096-1101.	1.3	591
34	Association of gastric intestinal metaplasia and East Asian ethnicity with the risk of gastric adenocarcinoma in a U.S. population. Gastrointestinal Endoscopy, 2018, 87, 1023-1028.	1.0	30
35	The Effect of Endoscopic Surveillance in Patients With Barrett's Esophagus: A Systematic Review and Meta-analysis. Gastroenterology, 2018, 154, 2068-2086.e5.	1.3	128
36	Surgical vs Endoscopic Management of T1 Esophageal Adenocarcinoma: A Modeling Decision Analysis. Clinical Gastroenterology and Hepatology, 2018, 16, 392-400.e7.	4.4	17

#	ARTICLE	IF	CITATIONS
37	Objective Differences in Colonoscopy Technique Between Trainee and Expert Endoscopists Using the Colonoscopy Force Monitor. Digestive Diseases and Sciences, 2018, 63, 46-52.	2.3	5
38	Endoscopic surveillance or ablation for Barrett's esophagus?. Translational Gastroenterology and Hepatology, 2018, 3, 102-102.	3.0	0
39	Low-Value Colorectal Cancer Screening. JAMA Network Open, 2018, 1, e185445.	5.9	2
40	Screening and Surveillance for Barrett's Esophagus: Is It Cost-Effective?. Digestive Diseases and Sciences, 2018, 63, 2094-2104.	2.3	26
41	Why "More Research Is Needed," Despite Overall Certainty: Women and Colorectal Cancer Screening. Annals of Internal Medicine, 2018, 168, 824-825.	3.9	1
42	Recent advances in Barrett's esophagus. Annals of the New York Academy of Sciences, 2018, 1434, 227-238.	3.8	12
43	Radiofrequency Ablation of Barrett's Esophagus Reduces Esophageal Adenocarcinoma Incidence and Mortality in a Comparative Modeling Analysis. Clinical Gastroenterology and Hepatology, 2017, 15, 1471-1474.	4.4	20
44	Taxonomy for colorectal cancer screening promotion: Lessons from recent randomized controlled trials. Preventive Medicine, 2017, 101, 229-234.	3.4	4
45	Editorial: Endoscopic Sedation: Who, Which, When?. American Journal of Gastroenterology, 2017, 112, 303-305.	0.4	8
46	Screening for Colorectal Neoplasia. New England Journal of Medicine, 2017, 376, 149-156.	27.0	86
47	Cost Effectiveness of Screening Patients With Gastroesophageal Reflux Disease for Barrett's Esophagus With a Minimally Invasive Cell Sampling Device. Clinical Gastroenterology and Hepatology, 2017, 15, 1397-1404.e7.	4.4	51
48	Follow-up of Positive Fecal Test Results. JAMA - Journal of the American Medical Association, 2017, 317, 1627.	7.4	2
49	Screening for Colorectal Neoplasia. New England Journal of Medicine, 2017, 376, 1598-1600.	27.0	16
50	Quality indicators for gastrointestinal endoscopy units. VideoGIE, 2017, 2, 119-140.	0.7	34
51	Development of Quality Indicators for Endoscopic Eradication Therapies in Barrett's Esophagus: The TREAT-BE (Treatment With Resection and Endoscopic Ablation Techniques for Barrett's Esophagus) Consortium. American Journal of Gastroenterology, 2017, 112, 1032-1048.	0.4	38
52	Development of quality indicators for endoscopic eradication therapies in Barrett's esophagus: the TREAT-BE (Treatment with Resection and Endoscopic Ablation Techniques for Barrett's Esophagus) Consortium. Gastrointestinal Endoscopy, 2017, 86, 1-17.e3.	1.0	50
53	The Impact of a Prior Diagnosis of Barrett's Esophagus on Esophageal Adenocarcinoma Survival. American Journal of Gastroenterology, 2017, 112, 1256-1264.	0.4	45
54	Increased Post-procedural Non-gastrointestinal Adverse Events After Outpatient Colonoscopy in High-risk Patients. Clinical Gastroenterology and Hepatology, 2017, 15, 883-891.e9.	4.4	14

#	ARTICLE	IF	CITATIONS
55	Introduction of Clinical Practice Update Committee Articles. Clinical Gastroenterology and Hepatology, 2017, 15, 4.	4.4	4
56	Time to Diagnostic Testing After a Positive Colorectal Cancer Screening Test—Reply. JAMA - Journal of the American Medical Association, 2017, 318, 483.	7.4	1
57	Effectiveness and Cost-Effectiveness of Endoscopic Screening and Surveillance. Gastrointestinal Endoscopy Clinics of North America, 2017, 27, 397-421.	1.4	19
58	Development of a Practical Model for Targeting Patient Decision Support Interventions to Promote Colorectal Cancer Screening in Vulnerable Populations. Journal of Health Care for the Poor and Underserved, 2016, 27, 465-478.	0.8	0
59	Racial/Ethnic Disparities in Colorectal Cancer Screening Across Healthcare Systems. American Journal of Preventive Medicine, 2016, 51, e107-e115.	3.0	67
60	A simple scoring system to assess the need for an endoscopic intervention in suspected upper gastrointestinal bleeding: A prospective cohort study. Digestive and Liver Disease, 2016, 48, 1180-1186.	0.9	18
61	Screening for Colorectal Cancer and Evolving Issues for Physicians and Patients. JAMA - Journal of the American Medical Association, 2016, 316, 2135.	7.4	65
62	Reply. Gastroenterology, 2016, 151, 564.	1.3	1
63	The impact of medical tourism on colorectal screening among Korean Americans: A community-based cross-sectional study. BMC Cancer, 2016, 16, 931.	2.6	11
64	Introduction to Clinical Practice Update Committee Articles. Gastroenterology, 2016, 151, 45.	1.3	0
65	Colorectal Cancer Screening. JAMA Oncology, 2016, 2, 1001.	7.1	1
66	Risks Associated With Anesthesia Services During Colonoscopy. Gastroenterology, 2016, 150, 888-894.	1.3	167
67	Adherence to Competing Strategies for Colorectal Cancer Screening Over 3 Years. American Journal of Gastroenterology, 2016, 111, 105-114.	0.4	93
68	The Impact of Uncertainty in Barrett's Esophagus Progression Rates on Hypothetical Screening and Treatment Decisions. Medical Decision Making, 2015, 35, 726-733.	2.4	6
69	Association of Visceral Fat Area, Smoking, and Alcohol Consumption with Reflux Esophagitis and Barrett's Esophagus in Japan. PLoS ONE, 2015, 10, e0133865.	2.5	47
70	An Accurate Cancer Incidence in Barrett's Esophagus: A Best Estimate Using Published Data and Modeling. Gastroenterology, 2015, 149, 577-585.e4.	1.3	37
71	Optimising colorectal cancer screening acceptance: a review. Gut, 2015, 64, 1158-1177.	12.1	92
72	Comparing the effectiveness of competing tests for reducing colorectal cancer mortality: a network meta-analysis. Gastrointestinal Endoscopy, 2015, 81, 700-709.e3.	1.0	48

#	ARTICLE	IF	CITATIONS
73	The Role of Gastroesophageal Reflux and Other Factors during Progression to Esophageal Adenocarcinoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1012-1023.	2.5	35
74	Race/Ethnicity and Primary Language: Health Beliefs about Colorectal Cancer Screening in a Diverse, Low-Income Population. <i>Journal of Health Care for the Poor and Underserved</i> , 2015, 26, 824-838.	0.8	14
75	Cost considerations in implementing a screening and surveillance strategy for Barrett's oesophagus. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2015, 29, 51-63.	2.4	10
76	BOB CAT: a Large-Scale Review and Delphi Consensus for Management of Barrett's Esophagus With No Dysplasia, Indefinite for, or Low-Grade Dysplasia. <i>American Journal of Gastroenterology</i> , 2015, 110, 662-682.	0.4	116
77	Gut epithelial barrier and systemic inflammation during chronic HIV infection. <i>Aids</i> , 2015, 29, 43-51.	2.2	156
78	Quality Indicators for the Management of Barrett's Esophagus, Dysplasia, and Esophageal Adenocarcinoma: International Consensus Recommendations from the American Gastroenterological Association Symposium. <i>Gastroenterology</i> , 2015, 149, 1599-1606.	1.3	81
79	Protective association of colonoscopy against proximal and distal colon cancer and patterns in interval cancer. <i>Gastrointestinal Endoscopy</i> , 2015, 82, 529-537.e1.	1.0	38
80	Quality Indicators for EGD. <i>American Journal of Gastroenterology</i> , 2015, 110, 60-71.	0.4	44
81	Quality indicators for EGD. <i>Gastrointestinal Endoscopy</i> , 2015, 81, 17-30.	1.0	107
82	Gastric Cancer in Asian American Populations: a Neglected Health Disparity. <i>Asian Pacific Journal of Cancer Prevention</i> , 2015, 15, 10565-10571.	1.2	29
83	Sedation Issues in Colonoscopy: Quality and Economic Considerations. , 2015, , 141-151.		0
84	Non-physician performance of lower and upper endoscopy: a systematic review and meta-analysis. <i>Endoscopy</i> , 2014, 46, 401-410.	1.8	39
85	Survival Benefit of Repeat Liver Transplantation in the United States: A Serial MELD Analysis by Hepatitis C Status and Donor Risk Index. <i>American Journal of Transplantation</i> , 2014, 14, 2588-2594.	4.7	22
86	Importance of Determining Indication for Colonoscopy: Implications for Practice and Policy. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1958-1963.e3.	4.4	11
87	Greater loss of productivity among Japanese workers with gastroesophageal reflux disease (<sc>GERD</sc>) symptoms that persist <i>vs</i> resolve on medical therapy. <i>Neurogastroenterology and Motility</i> , 2014, 26, 764-771.	3.0	11
88	Exploring the Recent Trend in Esophageal Adenocarcinoma Incidence and Mortality Using Comparative Simulation Modeling. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 997-1006.	2.5	61
89	Protective role of gluteofemoral obesity in erosive oesophagitis and Barrett's oesophagus. <i>Gut</i> , 2014, 63, 230-235.	12.1	37
90	Esophageal varices on computed tomography and subsequent variceal hemorrhage. <i>Abdominal Imaging</i> , 2014, 39, 251-256.	2.0	16

#	ARTICLE	IF	CITATIONS
91	Patient Trust in Physician Influences Colorectal Cancer Screening in Low-Income Patients. American Journal of Preventive Medicine, 2014, 47, 417-423.	3.0	64
92	Comparing Trends in Esophageal Adenocarcinoma Incidence and Lifestyle Factors Between the United States, Spain, and The Netherlands. American Journal of Gastroenterology, 2014, 109, 336-343.	0.4	45
93	A Combined Paging Alert and Web-Based Instrument Alters Clinician Behavior and Shortens Hospital Length of Stay in Acute Pancreatitis. American Journal of Gastroenterology, 2014, 109, 306-315.	0.4	30
94	Association Between Helicobacter pylori and Barrett's Esophagus, Erosive Esophagitis, and Gastroesophageal Reflux Symptoms. Clinical Gastroenterology and Hepatology, 2014, 12, 239-245.	4.4	110
95	Diversity of endoscopy center operations and practice variation across California's safety-net hospital system: a statewide survey. BMC Research Notes, 2013, 6, 233.	1.4	6
96	Approach to the Patient with Chest Pain. , 2013, , 11-17.		0
97	How to Recognize a Good Guideline. Gastroenterology, 2013, 145, 1179-1181.	1.3	2
98	Associations of Diabetes Mellitus, Insulin, Leptin, and Ghrelin With Gastroesophageal Reflux and Barrett's Esophagus. Gastroenterology, 2013, 145, 1237-1244.e5.	1.3	78
99	American Gastroenterological Association Institute Technical Review on the Use of Thiopurines, Methotrexate, and Anti-TNF- α Biologic Drugs for the Induction and Maintenance of Remission in Inflammatory Crohn's Disease. Gastroenterology, 2013, 145, 1464-1478.e5.	1.3	196
100	The AGA Institute Process for Developing Clinical Practice Guidelines Part One: Grading the Evidence. Clinical Gastroenterology and Hepatology, 2013, 11, 329-332.	4.4	73
101	How to Value Technological Innovation: A Proposal for Determining Relative Clinical Value. Gastroenterology, 2013, 144, 5-8.	1.3	17
102	Late Presentation of Colorectal Cancer in a Vulnerable Population. American Journal of Gastroenterology, 2013, 108, 466-470.	0.4	9
103	Anesthesia for Colonoscopy: Too Much of a Good Thing?. JAMA Internal Medicine, 2013, 173, 556.	5.1	5
104	Prediction of Barrett's Esophagus Among Men. American Journal of Gastroenterology, 2013, 108, 353-362.	0.4	159
105	Diverticular Disease of the Colon. , 2013, , 278-284.		0
106	Tumors of the Stomach. , 2013, , 247-255.		1
107	Why You Should Care about Screening Flexible Sigmoidoscopy. New England Journal of Medicine, 2012, 366, 2421-2422.	27.0	12
108	Adherence to Colorectal Cancer Screening. Archives of Internal Medicine, 2012, 172, 575.	3.8	473

#	ARTICLE	IF	CITATIONS
109	Projected future increase in aging hepatitis C virus–infected liver transplant candidates: A potential effect of hepatocellular carcinoma. <i>Liver Transplantation</i> , 2012, 18, 1471-1478.	2.4	66
110	Maintenance of Heartburn Relief After Step-Down From Twice-Daily Proton Pump Inhibitor to Once-Daily Dexlansoprazole Modified Release. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 247-253.	4.4	51
111	Consensus Statements for Management of Barrett's Dysplasia and Early-Stage Esophageal Adenocarcinoma, Based on a Delphi Process. <i>Gastroenterology</i> , 2012, 143, 336-346.	1.3	365
112	The Cost Effectiveness of Radiofrequency Ablation for Barrett's Esophagus. <i>Gastroenterology</i> , 2012, 143, 567-575.	1.3	143
113	Is 325 mg of Prevention Worth a Pound of Cure?. <i>Gastroenterology</i> , 2012, 143, 885-887.	1.3	0
114	Classification of functional dyspepsia based on concomitant bowel symptoms. <i>Neurogastroenterology and Motility</i> , 2012, 24, 325.	3.0	61
115	Adverse events after screening and follow-up colonoscopy. <i>Cancer Causes and Control</i> , 2012, 23, 289-296.	1.8	94
116	Time to Burn? Endoscopic Ablation for Barrett's Esophagus. <i>Gastroenterology</i> , 2011, 141, 417-419.	1.3	9
117	American Gastroenterological Association Medical Position Statement on the Management of Barrett's Esophagus. <i>Gastroenterology</i> , 2011, 140, 1084-1091.	1.3	909
118	American Gastroenterological Association Technical Review on the Management of Barrett's Esophagus. <i>Gastroenterology</i> , 2011, 140, e18-e52.	1.3	968
119	Adverse events in older patients undergoing colonoscopy: a systematic review and meta-analysis. <i>Gastrointestinal Endoscopy</i> , 2011, 74, 885-896.	1.0	219
120	Comparisons of Screening Colonoscopy Performed by a Nurse Practitioner and Gastroenterologists. <i>Gastroenterology Nursing</i> , 2011, 34, 210-216.	0.4	40
121	Cost-Effective Treatment of Patients with Symptomatic Cholelithiasis and Possible Common Bile Duct Stones. <i>Journal of the American College of Surgeons</i> , 2011, 212, 1049-1060e7.	0.5	61
122	Reduced Effectiveness of Standard Recruitment for Deceased Organ Donor Registration: The Need for Population-Specific Recruitment Materials. <i>Digestive Diseases and Sciences</i> , 2011, 56, 1535-1541.	2.3	3
123	Validation of a New Physical Activity Questionnaire for a Sedentary Population. <i>Digestive Diseases and Sciences</i> , 2011, 56, 2678-2687.	2.3	16
124	Prevalence of gastric cancer versus colorectal cancer in Asians with a positive fecal occult blood test. <i>Indian Journal of Gastroenterology</i> , 2011, 30, 209-216.	1.4	7
125	Moderate ascites identifies patients with low model for end-stage liver disease scores awaiting liver transplantation who have a high mortality risk. <i>Liver Transplantation</i> , 2011, 17, 129-136.	2.4	70
126	Esophageal Adenocarcinoma Incidence in Individuals With Gastroesophageal Reflux: Synthesis and Estimates From Population Studies. <i>American Journal of Gastroenterology</i> , 2011, 106, 254-260.	0.4	79

#	ARTICLE	IF	CITATIONS
127	Maintenance of Heartburn Symptom Relief in Patients Stepped-Down from Twice-Daily Proton Pump Inhibitor to Once-Daily Dexlansoprazole MR. American Journal of Gastroenterology, 2011, 106, S5-S6.	0.4	0
128	Race and Inflammatory Bowel Disease in an Urban Healthcare System. Digestive Diseases and Sciences, 2010, 55, 3479-3487.	2.3	43
129	Hospitalizations are increasing among minority patients with Crohn's disease and ulcerative colitis. Inflammatory Bowel Diseases, 2010, 16, 204-207.	1.9	42
130	Interval Cancers After Colonoscopy: The Importance of Training. American Journal of Gastroenterology, 2010, 105, 2597-2598.	0.4	3
131	Colorectal Cancer Screening Compliance and Contemplation in Gynecology Patients. Journal of Women's Health, 2010, 19, 911-917.	3.3	14
132	Projected increased growth rate of anesthesia professionalâ€delivered sedation for colonoscopy and EGD in the United States: 2009 to 2015. Gastrointestinal Endoscopy, 2010, 72, 580-586.	1.0	106
133	The Development of Clinical Guidelines by the American Gastroenterological Association. Gastroenterology, 2010, 138, 417-418.	1.3	4
134	Issues Related to BID Dosing of PPIs. Gastroenterology and Hepatology, 2010, 6, 369-70.	0.1	0
135	Magnitude and economic effect of overuse of antisecretory therapy in the ambulatory care setting. American Journal of Managed Care, 2010, 16, e228-34.	1.1	100
136	Overutilization of Proton Pump Inhibitors. American Journal of Gastroenterology, 2009, 104, S27-S32.	0.4	0
137	Response to Meyer, Dominic et al., and Lin and Schembre. American Journal of Gastroenterology, 2009, 104, 2628-2629.	0.4	3
138	Potential for Lead-Time and Length-Time Biases in Outcomes in Esophageal Adenocarcinoma. American Journal of Gastroenterology, 2009, 104, 3106-3107.	0.4	3
139	Response to Fujita and Kapoor. American Journal of Gastroenterology, 2009, 104, 244-245.	0.4	2
140	National Institutes of Health consensus development conference statement: Management of hepatitis B. Hepatology, 2009, 49, S4-S12.	7.3	91
141	Ascites improves upon plus serum sodium model for end-stage liver disease (MELD) for predicting mortality in patients with advanced liver disease. Alimentary Pharmacology and Therapeutics, 2009, 30, 741-748.	3.7	25
142	Japanese herbal medicine in functional gastrointestinal disorders. Neurogastroenterology and Motility, 2009, 21, 688-696.	3.0	93
143	Transplant tourism to China: the impact on domestic patient's care decisions. Clinical Transplantation, 2009, 23, 831-838.	1.6	12
144	Projected Growth Rate of Anesthesiologist-Delivered Sedation in Colonoscopy and EGD in the United States: 2009- 2011. Gastrointestinal Endoscopy, 2009, 69, AB111.	1.0	2

#	ARTICLE	IF	CITATIONS
145	Pragmatic classification of superficial neoplastic colorectal lesions. <i>Gastrointestinal Endoscopy</i> , 2009, 70, 1182-1199.	1.0	112
146	A Cost-Utility Analysis of Ablative Therapy for Barrett's Esophagus. <i>Gastroenterology</i> , 2009, 136, 2101-2114.e6.	1.3	174
147	New Model for End Stage Liver Disease Improves Prognostic Capability After Transjugular Intrahepatic Portosystemic Shunt. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 1236-1240.	4.4	31
148	Esophageal Varices On Computed Tomography Predicts Variceal Hemorrhage. <i>Gastrointestinal Endoscopy</i> , 2009, 69, AB355-AB356.	1.0	0
149	American College of Gastroenterology Guidelines for Colorectal Cancer Screening 2008. <i>American Journal of Gastroenterology</i> , 2009, 104, 739-750.	0.4	1,258
150	Overutilization of Proton Pump Inhibitors: A Review of Cost-Effectiveness and Risk in PPI. <i>American Journal of Gastroenterology</i> , 2009, 104, S27-S32.	0.4	139
151	Non-English Speakers Attend Gastroenterology Clinic Appointments at Higher Rates Than English Speakers in a Vulnerable Patient Population. <i>Journal of Clinical Gastroenterology</i> , 2009, 43, 652-660.	2.2	13
152	National Institutes of Health Consensus Development Conference Statement: Management of Hepatitis B. <i>Annals of Internal Medicine</i> , 2009, 150, 104.	3.9	329
153	Surveillance in Barrett's Esophagus: A Failed Premise. <i>Keio Journal of Medicine</i> , 2009, 58, 12-18.	1.1	23
154	Updates in colorectal cancer screening. <i>F1000 Medicine Reports</i> , 2009, 1, .	2.9	0
155	A Cost-Identification Analysis of Screening and Surveillance of Hepatitis C Infection in a Prospective Cohort of Dialysis Patients. <i>Digestive Diseases and Sciences</i> , 2008, 53, 1093-1099.	2.3	5
156	Taishotoyama Symposium Barriers to colorectal cancer screening: Economics, capacity and adherence. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, S198-204.	2.8	11
157	Fear of Loss, Not Promise of Gain, Drives Practice Patterns in Barrett's Esophagus. <i>Gastroenterology</i> , 2008, 134, 1258-1260.	1.3	0
158	In Search of Quality Colonoscopy. <i>Gastroenterology</i> , 2008, 135, 1845-1847.	1.3	12
159	Effect of a prior endoscopy on outcomes of esophageal adenocarcinoma among United States veterans. <i>Gastrointestinal Endoscopy</i> , 2008, 68, 849-855.	1.0	88
160	Nonpolypoid neoplastic lesions of the colorectal mucosa. <i>Gastrointestinal Endoscopy</i> , 2008, 68, S3-S47.	1.0	457
161	Management of Obscure Occult Gastrointestinal Bleeding: A Cost-Minimization Analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2008, 6, 661-670.	4.4	54
162	A Pilot Study of the Association of Low Plasma Adiponectin and Barrett's Esophagus. <i>American Journal of Gastroenterology</i> , 2008, 103, 1358-1364.	0.4	63

#	ARTICLE	IF	CITATIONS
163	Systematic Review of the Predictors of Recurrent Hemorrhage After Endoscopic Hemostatic Therapy for Bleeding Peptic Ulcers. American Journal of Gastroenterology, 2008, 103, 2625-2632.	0.4	162
164	Magnitude and Economic Impact of Inappropriate Use of Proton Pump Inhibitors for Treatment of Upper Gastrointestinal Disorders in the Ambulatory Care Setting. American Journal of Gastroenterology, 2008, 103, S403.	0.4	1
165	Pilot Study of Colonoscopy by Nurse Practitioner for Colorectal Cancer (CRC) Screening in a Safety Net Healthcare System. American Journal of Gastroenterology, 2008, 103, S549.	0.4	0
166	Pay for Performance: ACG Guide for Physicians. American Journal of Gastroenterology, 2007, 102, 2119-2122.	0.4	15
167	On-Demand Therapy for Gastroesophageal Reflux Disease. American Journal of Gastroenterology, 2007, 102, 642-653.	0.4	66
168	Association of Hepatitis C Seropositivity With Increased Risk for Developing End-stage Renal Disease. Archives of Internal Medicine, 2007, 167, 1271.	3.8	147
169	Risk Stratification in Upper Gastrointestinal Bleeding. Journal of Clinical Gastroenterology, 2007, 41, 559-563.	2.2	8
170	The Cost-Effectiveness of CT Colonography in Screening for Colorectal Neoplasia. American Journal of Gastroenterology, 2007, 102, 380-390.	0.4	111
171	Cost Utility of Screening for Barrett's Esophagus With Esophageal Capsule Endoscopy Versus Conventional Upper Endoscopy. Clinical Gastroenterology and Hepatology, 2007, 5, 312-318.	4.4	83
172	Patients prefer conventional to virtual colonoscopy. Gastroenterology, 2007, 132, 809-811.	1.3	0
173	Proton Pump Inhibitors and Hip Fracture: Cause for Alarm?. Gastroenterology, 2007, 132, 2063-2065.	1.3	0
174	AGA Institute Review of Endoscopic Sedation. Gastroenterology, 2007, 133, 675-701.	1.3	398
175	Will Virtual Colonoscopy Replace Optical Colonoscopy for Colorectal Cancer Screening?. Gastroenterology, 2007, 133, 1384-1385.	1.3	0
176	Colorectal Cancer Screening in Gynecology Patients. Gastrointestinal Endoscopy, 2007, 65, AB263.	1.0	0
177	Oesophageal hypersensitivity is associated with features of psychiatric disorders and the irritable bowel syndrome. Alimentary Pharmacology and Therapeutics, 2007, 26, 443-452.	3.7	48
178	Screening for esophageal cancer and Barrett's esophagus. Current GERD Reports, 2007, 1, 185-192.	0.1	0
179	Patients That Do Not Speak English Miss Fewer Clinic Appointments Than English Speaking Patients. American Journal of Gastroenterology, 2007, 102, S434.	0.4	0
180	Exploring Utilities and Outcomes With Infliximab Therapy. Clinical Gastroenterology and Hepatology, 2006, 4, 976-978.	4.4	3

#	ARTICLE	IF	CITATIONS
181	When to stop screening for colorectal cancer. <i>Gastroenterology</i> , 2006, 131, 1355-1357.	1.3	0
182	Implementing a research project: the nitty gritty. <i>Gastrointestinal Endoscopy</i> , 2006, 64, S7-S10.	1.0	1
183	Defining a Clinically Significant Adverse Impact of Diagnosing Barrett's Esophagus. <i>Journal of Clinical Gastroenterology</i> , 2006, 40, 109-115.	2.2	13
184	Primary care physician perceptions of non-steroidal anti-inflammatory drug and aspirin-associated toxicity: results of a national survey. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 23, 655-668.	3.7	14
185	Suboptimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastroesophageal reflux disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 23, 1473-1477.	3.7	116
186	Evidence Based Medicine (EBM) in Practice: Applying Results of Cost-Effectiveness Analyses. <i>American Journal of Gastroenterology</i> , 2006, 101, 1169-1171.	0.4	5
187	Magnitude and Economic Impact of Inappropriate Use of Stress Ulcer Prophylaxis in Non-ICU Hospitalized Patients. <i>American Journal of Gastroenterology</i> , 2006, 101, 2200-2205.	0.4	142
188	Prior Endoscopy Does Not Improve Long-Term Survival from Esophageal Adenocarcinoma among United States Veterans. <i>American Journal of Gastroenterology</i> , 2006, 101, S46-S47.	0.4	2
189	The cost-effectiveness of biomarkers for predicting the development of oesophageal adenocarcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 22, 135-146.	3.7	25
190	Relationship between diabetes mellitus and adenocarcinoma of the oesophagus and gastric cardia. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 22, 267-271.	3.7	35
191	Primary-Care Physicians' Perceptions and Practices on the Management of GERD: Results of a National Survey. <i>American Journal of Gastroenterology</i> , 2005, 100, 1237-1242.	0.4	56
192	Women patients' preference for women physicians is a barrier to colon cancer screening. <i>Gastrointestinal Endoscopy</i> , 2005, 62, 219-223.	1.0	117
193	Dysphagia drives doctors to diagnose a disease: pitfalls in interpreting observational studies. <i>Gastrointestinal Endoscopy</i> , 2005, 61, 809-811.	1.0	2
194	PPI use in the OTC era: Who to treat, with what, and for how long?. <i>Clinical Gastroenterology and Hepatology</i> , 2005, 3, 208-215.	4.4	31
195	Adherence to Competing Colorectal Cancer Screening Strategies. <i>American Journal of Gastroenterology</i> , 2005, 100, S387-S388.	0.4	10
196	Relationship Between Diabetes Mellitus and Adenocarcinoma of the Esophagus and Gastric Cardia. <i>American Journal of Gastroenterology</i> , 2005, 100, S23.	0.4	0
197	Magnitude and Economic Impact of Inappropriate Use of Stress Ulcer Prophylaxis in Non-Intensive Care Unit Hospitalized Patients. <i>American Journal of Gastroenterology</i> , 2005, 100, S274.	0.4	0
198	What is the best management strategy for high grade dysplasia in Barrett's oesophagus? A cost effectiveness analysis. <i>Gut</i> , 2004, 53, 1736-1744.	12.1	80

#	ARTICLE	IF	CITATIONS
199	A Cost-Utility Analysis of Secondary Prophylaxis for Variceal Hemorrhage. American Journal of Gastroenterology, 2004, 99, 1274-1288.	0.4	27
200	Projections of demand and capacity for colonoscopy related to increasing rates of colorectal cancer screening in the United States. Alimentary Pharmacology and Therapeutics, 2004, 20, 507-515.	3.7	125
201	Women's Preference for Women Physicians Is a Barrier to Colorectal Cancer Screening. Gastrointestinal Endoscopy, 2004, 59, P109.	1.0	1
202	I Once Caught a Fish This Big: Endoscopists' Estimate of Polyp Size. Gastrointestinal Endoscopy, 2004, 59, P274.	1.0	0
203	Decision analysis and economic modelling. European Journal of Gastroenterology and Hepatology, 2004, 16, 535-542.	1.6	36
204	A glossary of economic terms. European Journal of Gastroenterology and Hepatology, 2004, 16, 563-565.	1.6	4
205	Empiric H ² -blockers for the prophylaxis of variceal hemorrhage: Cost effective or clinically applicable?. Hepatology, 2003, 37, 249-252.	7.3	6
206	The economic impact of irritable bowel syndrome. Alimentary Pharmacology and Therapeutics, 2003, 18, 671-682.	3.7	146
207	An evidence-based medicine approach to economic studies: assessing the cost-effectiveness of competing strategies for colorectal cancer screening. Clinical Gastroenterology and Hepatology, 2003, 1, 404-413.	4.4	4
208	What is the best management strategy for high grade dysplasia (HGD) in Barrett's esophagus? A cost-effectiveness analysis. Gastroenterology, 2003, 124, A33-A34.	1.3	0
209	Spontaneous passage of a pancreatic duct stone. Gastrointestinal Endoscopy, 2003, 57, 278-280.	1.0	2
210	Step-down from multiple- to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completely relieved with PPIs. American Journal of Gastroenterology, 2003, 98, 1940-1944.	0.4	162
211	Update on the cost-effectiveness of screening for colorectal neoplasia. Current Opinion in Gastroenterology, 2003, 19, 44-50.	2.3	9
212	Screening and Surveillance for Barrett Esophagus in High-Risk Groups: A CostUtility Analysis. Annals of Internal Medicine, 2003, 138, 176.	3.9	330
213	The Impact of a Celebrity Promotional Campaign on the Use of Colon Cancer Screening. Archives of Internal Medicine, 2003, 163, 1601.	3.8	329
214	Prevention of Complicated Ulcer Disease Among Chronic Users of Nonsteroidal Anti-inflammatory Drugs. Archives of Internal Medicine, 2002, 162, 2105.	3.8	44
215	On-Demand and Intermittent Therapy for Gastro-Oesophageal Reflux Disease. Pharmacoeconomics, 2002, 20, 565-576.	3.3	24
216	Step-down management of gastroesophageal reflux disease. Gastroenterology, 2001, 121, 1095-1100.	1.3	177

#	ARTICLE	IF	CITATIONS
217	Cost-effectiveness of once in a lifetime screening unsedated endoscopy in 50 year-old white males with uncomplicated GERD. <i>Gastroenterology</i> , 2001, 120, A414.	1.3	2
218	The Laparoscopic Evaluation of Ascites. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2001, 11, 79-91.	1.4	27
219	Unsedated Small-caliber Esophagogastroduodenoscopy (EGD). <i>Journal of Clinical Gastroenterology</i> , 2001, 33, 210-214.	2.2	29
220	Lansoprazole Treatment of Patients With Chronic Idiopathic Laryngitis: A Placebo-Controlled Trial. <i>American Journal of Gastroenterology</i> , 2001, 96, 979-983.	0.4	186
221	Screening for Hereditary Hemochromatosis in Siblings and Children of Affected Patients: A Cost-Effectiveness Analysis. <i>Annals of Internal Medicine</i> , 2000, 132, 261.	3.9	63
222	Cost-Effectiveness of Colonoscopy in Screening for Colorectal Cancer. <i>Annals of Internal Medicine</i> , 2000, 133, 573.	3.9	428
223	The impact of colorectal cancer screening on life expectancy. <i>Gastrointestinal Endoscopy</i> , 2000, 51, 517-523.	1.0	54
224	3718 SMALL CALIBER ESOPHAGOGASTRODUODENOSCOPY WITHOUT SEDATION: LESS EXPENSIVE AND LESS TIME CONSUMING THAN CONVENTIONAL ENDOSCOPY.. <i>Gastrointestinal Endoscopy</i> , 2000, 51, AB135.	1.0	2
225	Clinical and economic impact of population-based screening for hepatitis C: A decision analysis. <i>Gastroenterology</i> , 2000, 118, A1001.	1.3	0
226	Determinants of intestinal metaplasia in the antrum, corpus, and cardia of the stomach. <i>Gastroenterology</i> , 2000, 118, A749.	1.3	0
227	Is step-down from PPIs feasible? Prospective evaluation of a practice guideline for gastroesophageal reflux disease. <i>Gastroenterology</i> , 2000, 118, A212.	1.3	0
228	Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. <i>Journal of Hepatology</i> , 2000, 32, 142-153.	3.7	838
229	Corpus gastritis is protective against reflux oesophagitis. <i>Gut</i> , 1999, 45, 181-185.	12.1	147
230	Reliability Block Diagrams to Model Disease Management. <i>Medical Decision Making</i> , 1999, 19, 180-185.	2.4	5
231	Economic analysis of step-wise treatment of gastro-oesophageal reflux disease. <i>Alimentary Pharmacology and Therapeutics</i> , 1999, 13, 1003-1013.	3.7	19
232	Reliability block diagrams to model the management of colorectal cancer. <i>Digestive Diseases and Sciences</i> , 1999, 44, 314-321.	2.3	5
233	Chronic corpus gastritis is protective against erosive esophagitis. <i>Gastroenterology</i> , 1998, 114, A113.	1.3	1
234	Cost analysis of alternative therapies for primary and secondary prophylaxis of variceal bleeding. <i>Gastroenterology</i> , 1998, 114, A589.	1.3	1

#	ARTICLE	IF	CITATIONS
235	The Impact of Peptic Ulcer Disease and Infection With <i>Helicobacter pylori</i> On Life Expectancy. American Journal of Gastroenterology, 1998, 93, 1286-1290.	0.4	14
236	Cost-analysis of prophylactic antibiotics in spontaneous bacterial peritonitis. Gastroenterology, 1997, 113, 1289-1294.	1.3	71
237	Ultrasonographic determination of ascitic volume. Hepatology, 1996, 24, 549-551.	7.3	34
238	Economic Analysis in the Diagnosis and Treatment of Gastrointestinal Diseases. , 0, , 14-19.		0
239	Structural Anomalies, Tumors, and Diseases of the Biliary Tract. , 0, , 358-365.		0
240	Approach to the Patient with Gastrointestinal Bleeding. , 0, , 18-39.		0
241	Infections of the Gastrointestinal Tract. , 0, , 451-470.		0
242	End-stage Liver Disease. , 0, , 432-442.		0
243	Pancreatic Adenocarcinoma. , 0, , 349-357.		0
244	Colonic Neoplasia. , 0, , 306-322.		0
245	Vascular Lesions. , 0, , 471-478.		1
246	Anorectal Diseases. , 0, , 323-334.		0
247	Biliary Tract Stones and Postcholecystectomy Syndrome. , 0, , 366-376.		0
248	Cholestatic Syndromes. , 0, , 412-419.		0
249	Approach to the Patient with Constipation. , 0, , 89-98.		0
250	Acid Peptic Disorders. , 0, , 232-240.		0
251	Esophageal Tumors. , 0, , 212-220.		0
252	Approach to the Patient with Unexplained Weight Loss. , 0, , 40-47.		0

#	ARTICLE	IF	CITATIONS
253	Approach to the Patient with Diarrhea. , 0 , 99-111.		0
254	Disorders of Gastric Emptying. , 0 , 221-231.		0
255	Approach to the Patient with an Abdominal Mass. , 0 , 112-120.		0
256	Approach to the Patient with Ileus or Obstruction. , 0 , 78-88.		0
257	Motor Disorders of the Esophagus. , 0 , 193-203.		0
258	Approach to the Patient with Abnormal Liver Biochemical Tests. , 0 , 135-147.		0
259	Short Bowel Syndrome. , 0 , 263-269.		0
260	Diseases of the Abdominal Cavity. , 0 , 377-390.		0
261	Nonviral Hepatitis. , 0 , 405-411.		0
262	Autoimmune Liver Disease. , 0 , 427-431.		0
263	Approach to the Patient with Dysphagia or Odynophagia. , 0 , 1-10.		1
264	Approach to the Patient with Gas and Bloating. , 0 , 70-77.		0
265	Approach to the Patient with Ascites. , 0 , 148-162.		0
266	Approach to the Patient with Abdominal Pain. , 0 , 58-69.		0
267	Approach to the Patient with Jaundice. , 0 , 121-134.		0
268	Approach to the Patient with Nausea and Vomiting. , 0 , 48-57.		0
269	Approach to the Patient Requiring Nutritional Support. , 0 , 163-177.		0
270	Tumors and Other Neoplastic Diseases of the Small Intestine. , 0 , 270-277.		0

#	ARTICLE	IF	CITATIONS
271	Approach to the Patient Requiring Endoscopic Procedures. , 0, , 178-191.		0
272	Functional Dyspepsia. , 0, , 241-246.		0